BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22305028)

  • 1. My treatment approach to patients with diffuse large B-cell lymphoma.
    Armitage JO
    Mayo Clin Proc; 2012 Feb; 87(2):161-71. PubMed ID: 22305028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of diffuse large B-cell lymphoma].
    Gleissner B; Zwick C; Pfreundschuh M
    Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
    Seki R; Ohshima K; Nagafuji K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Int J Hematol; 2010 Mar; 91(2):258-66. PubMed ID: 20066574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
    Persky DO; Li H; Stephens DM; Park SI; Bartlett NL; Swinnen LJ; Barr PM; Winegarden JD; Constine LS; Fitzgerald TJ; Leonard JP; Kahl BS; LeBlanc ML; Song JY; Fisher RI; Rimsza LM; Smith SM; Miller TP; Friedberg JW
    J Clin Oncol; 2020 Sep; 38(26):3003-3011. PubMed ID: 32658627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma.
    Ng AK
    Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
    Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
    Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.
    Han EJ; Lee SE; Kim SH; Sohn HS; Jung SE; Park G; Choi BO; Lee SN; Yang SW; Han K; Cho SG
    Ann Hematol; 2011 Sep; 90(9):1075-82. PubMed ID: 21336624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
    Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C
    J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.